

Endologix Inc (ELGX) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/E2B0610DE2DEN.html>

Date: April 2020

Pages: 48

Price: US\$ 125.00 (Single User License)

ID: E2B0610DE2DEN

Abstracts

Endologix Inc (ELGX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Endologix, Inc (Endologix) is a medical device company. It develops, manufactures and markets minimally invasive devices in treatment of aortic diseases. The company incorporates its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). The company's AAA products are built on traditional minimally-invasive endovascular repair (EVAR) platform or endovascular sealing (EVAS) platform and Ovation system. The company's EVAR products include AFX endovascular AAA system, the VELA proximal endograft, the ovation abdominal stent graft system. It has manufacturing facility in Irvine and Santa Rosa, California. The company sells products in the US and six other countries through direct sales force. It also sells products through third-party distributors and agents in Asia Pacific, Latin America, Europe and other targeted international geographies. Endologix is headquartered in Irvine, California, the US.

Endologix Inc Key Recent Developments

Apr 14,2020 Endologix appoints Tim A. Benner as chief commercial officer

Apr 06,2020 Endologix announces preliminary financial results for first quarter 2020

Mar 17,2020 Endologix adds Jane E. Kiernan to its board of directors

Feb 19,2020 Endologix reports fourth quarter and fiscal year 2019 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Endologix Inc - Key Facts
Endologix Inc - Key Employees
Endologix Inc - Key Employee Biographies
Endologix Inc - Major Products and Services
Endologix Inc - History
Endologix Inc - Company Statement
Endologix Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Endologix Inc - Business Description
Geographical Segment: International
Performance
Geographical Segment: The US
Performance
R&D Overview
Endologix Inc - Corporate Strategy
Endologix Inc - SWOT Analysis
SWOT Analysis - Overview
Endologix Inc - Strengths
Endologix Inc - Weaknesses
Endologix Inc - Opportunities
Endologix Inc - Threats
Endologix Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Endologix Inc, Medical Equipment, Deals By Year, 2014 to YTD 2020

Endologix Inc, Medical Equipment, Deals By Type, 2014 to YTD 2020

Endologix Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Apr 14, 2020: Endologix appoints Tim A. Benner as chief commercial officer

Apr 06, 2020: Endologix announces preliminary financial results for first quarter 2020

Mar 17, 2020: Endologix adds Jane E. Kiernan to its board of directors

Feb 19, 2020: Endologix reports fourth quarter and fiscal year 2019 financial results

Nov 06, 2019: Endologix reports third quarter 2019 financial results

Aug 08, 2019: Endologix reports second quarter 2019 financial results

May 02, 2019: Endologix reports first quarter 2019 financial results

Feb 25, 2019: Endologix announces fourth quarter and fiscal year 2018 financial results

Jan 10, 2019: Endologix names John D. Zehren as Chief Commercial Officer

Jan 07, 2019: Endologix Announces Fourth Quarter and Full-Year 2018 Preliminary Financial Results and Provides 2019 Financial Guidance

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Endologix Inc, Key Facts
Endologix Inc, Key Employees
Endologix Inc, Key Employee Biographies
Endologix Inc, Major Products and Services
Endologix Inc, History
Endologix Inc, Subsidiaries
Endologix Inc, Key Competitors
Endologix Inc, Ratios based on current share price
Endologix Inc, Annual Ratios
Endologix Inc, Annual Ratios (Cont...1)
Endologix Inc, Interim Ratios
Endologix Inc, Medical Equipment, Deals By Year, 2014 to YTD 2020
Endologix Inc, Medical Equipment, Deals By Type, 2014 to YTD 2020
Endologix Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Endologix Inc, Performance Chart (2015 - 2019)

Endologix Inc, Ratio Charts

Endologix Inc, Medical Equipment, Deals By Year, 2014 to YTD 2020

Endologix Inc, Medical Equipment, Deals by Type, 2014 to YTD 2020

COMPANIES MENTIONED

W. L. Gore & Associates Inc

St. Jude Medical LLC

Medtronic Plc

Lombard Medical Technologies Ltd

Cordis Corp

Cook Medical Inc

Aptus Endosystems Inc

I would like to order

Product name: Endologix Inc (ELGX) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/E2B0610DE2DEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E2B0610DE2DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970